Over 50,000 Cases in a Single Day! Inside the Speed of Landing AI's Cervical Cancer Screening | Dalton Venture Family

Preface

According to reports, Landing Medical — a Dalton Venture portfolio company — recently set a new record for AI-powered cervical cancer screening speed, achieving over 50,000 cases in a single day. From equipment that could only scan one specimen at a time, to high-throughput scanners capable of processing 200 slides simultaneously, and now to robotic workstations and an AI cervical cancer screening cloud platform that can complete 50,000 screenings per day, Landing has demonstrated breakthrough after breakthrough in applying artificial intelligence to early cancer detection and treatment.

Recently, Landing Medical showcased its next-generation intelligent scanning matrix and digital pathology workstation — core technology products — at the 21st National Conference on Cytopathology of the Chinese Medical Association, drawing widespread attention and high praise from attending experts. Debuting at the same event, Landing's "intelligent scanning matrix" became the undeniable star of the show, attracting numerous attendees. Many renowned experts also visited the Landing booth to exchange ideas.

This intelligent matrix, equipped with a high-precision 6-axis robotic arm, can scan 8,000–10,000 samples per day. It is designed for large-scale testing institutions to perform microscopic imaging scans of cell samples, with AI assisting physicians in cytological diagnosis.

Innovation and Breakthroughs

Next-Generation AI Digital Pathology Products

"Simple, user-friendly, and remarkably efficient!" After using Landing's portable intelligent cell/tissue pathology scanner to complete a rapid diagnosis of a pulmonary nodule, Zhu Zheng, director of Shenzhen University Affiliated South China Hospital, offered heartfelt praise for the device.

The Landing Portable Intelligent Cell/Tissue Pathology Scanner is a new intelligent scanning device independently developed by Landing Medical. It uses a color industrial camera with a custom imaging lens barrel, paired with a stepless dimming light source, to rapidly and automatically complete scanning and image processing. Through the Landing CytoBrain intelligent algorithm, it performs AI analysis of cervical cell images and flags suspicious cells. Compared to traditional large-scale cytopathology scanners, it boasts compact size, portability, and excellent cost performance — standout advantages that enable rapid scanning and upload of pathology cell samples anytime, anywhere, supporting remote consultation and quality control. Paired with an automatic slide-loading robotic arm, it can also achieve batch scanning, upload, and diagnosis, fully meeting pathologists' professional needs.

Landing Medical recently organized large-scale testing programs at Shanghai Ruijin Hospital, Wuhan Asia Heart Hospital, Taikang Tongji (Wuhan) Hospital, and other institutions. Pathology experts used the device to complete over 3,000 scans of cervical cell and non-gynecological cell diagnostic frozen imprints, successfully diagnosing over 95% of cases through the cloud diagnosis platform. Through these trials, experts highly praised the Landing Portable Intelligent Cell/Tissue Pathology Scanner, unanimously agreeing that the device can perform rapid intraoperative tissue diagnosis, assisting doctors with scanning and diagnosis of thyroid, cervical, lung, and other tissue pathologies. It can effectively reduce pathologists' workload, help junior cytopathologists improve diagnostic accuracy and reduce missed diagnoses, and assist senior cytopathologists in boosting diagnostic efficiency and significantly reducing slide review time.

The Future of Smart Healthcare

Digital Pathology Workstation

In martial arts, speed conquers all.

When it comes to AI-powered cervical cancer screening, the first and greatest advantage is speed.

Just how fast can AI cervical cancer screening go? Recently released data shows that Landing's AI cervical cancer screening cloud platform completed 50,000 cases in a single day — a new record.

For context, in 2022, during a cervical cancer screening program for 12.67 million women of appropriate age in Hubei Province, Landing completed over 1 million AI cervical cancer screenings in 50 days, maintaining an average pace of 20,000 cases per day. By comparison, traditional screening methods rely on manual microscopic examination to find cancer cells, with a maximum daily review volume of 100 slides per doctor.

The ever-increasing "Landing speed" stems from continuous iteration of AI screening technology. From equipment that could only scan one specimen at a time, to high-throughput scanners processing 200 slides simultaneously, Landing's intelligent scanning devices have been constantly upgrading. Landing's engineers even devised ways to pair automatic slide-loading robotic arms with their portable intelligent scanners, enabling automatic batch scanning and upload — efficient, rapid collection of clinical sample microscopic images anytime, anywhere.

The newly developed Landing AI Cervical Cancer Screening Robotic Workstation represents the future of smart healthcare — in an unmanned workstation, liquid-based cytology slide preparation, Papanicolaou staining, coverslipping, and other pathology cell slide production steps previously requiring manual labor have all become automated. This automated liquid-based cytology preparation, staining, and coverslipping system developed by Landing is equivalent to giving AI "hands," making it a true robot, achieving fully unmanned pipeline operation for cervical cancer screening.

Moreover, because AI never tires, AI cervical cancer screening capacity can theoretically expand without limit through automation and intelligent digital transformation of the entire industry chain. In the Hubei Province program for 12.67 million women, Landing Medical used artificial intelligence as its core technology, combined with 5G, IoT, cloud computing, and big data to achieve historic breakthroughs in the working model and capabilities of large-scale cervical cancer screening programs. The repeatedly shattered records fully demonstrate that AI technology is fully capable of handling massive screening tasks — making universal cervical cancer screening for hundreds of millions of women of appropriate age no longer a distant dream.

Openness and Collaboration

Empowering Early Cancer Detection and Treatment Through Digital AI Technology

On November 17, 2020, the World Health Organization released the Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. Since then, accelerating cervical cancer elimination has gained increasing attention from all quarters. In 2023, the National Health Commission of the People's Republic of China and nine other departments jointly formulated the Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030), aimed at speeding up China's cervical cancer elimination process. However, due to population size, medical resources, geography, and other factors, China still faces numerous practical challenges in effectively improving screening coverage. With 290 million women of appropriate age needing cervical cancer screening, but fewer than 20,000 pathologists nationwide, achieving universal screening goals requires making screening more efficient through digital and automation technologies — the only viable path.

As a technology company that pioneered AI-based cervical cancer cytology screening, Landing Medical has consistently pursued automation, intelligence, datafication, networking, standardization, and scaling of cytopathology diagnostic technology. Using AI-powered big data cloud diagnosis technology to serve early clinical diagnosis of various high-incidence tumors, Landing Medical has over the past 20 years enabled tens of millions of Chinese women to access high-quality, low-cost AI cervical cancer screening services. This successful practice has fully proven that AI cervical cancer screening technology is efficient, high-quality, suited to China's national conditions, and can effectively overcome the pain points of traditional screening models — fully capable of making significant contributions to eliminating cervical cancer in China and worldwide.

Currently, Landing's operations cover 31 provinces, autonomous regions, and municipalities across China, with clinical pathology diagnosis partnerships with over 2,100 hospitals. Going forward, Landing will continue to embrace an open collaborative approach, opening its AI big data cloud diagnosis platform to pathologists nationwide, providing platform services for the digital transformation of hospital pathology departments across the country, and jointly exploring new breakthroughs in AI technology for early cancer detection and treatment with pathology experts nationwide.

---

ID: daltonventure

Long press to follow

Recommended Reading